Categories
Lung Cancer

Lung Cancer Awareness – Ambulatory Precision Lung Sparing (A-PLUS) Surgery Program [Video]

Lung Cancer Awareness – Ambulatory Precision Lung Sparing (A-PLUS) Surgery Program

Dr. Samuel Kim, a thoracic surgeon at Northwestern Medicine discusses the Ambulatory Precision Lung Sparing (A-PLUS) surgery program born from the need to be able to screen and treat patients for lung cancer during the pandemic. The doctors at Northwestern Medicine spent the past several years honing this highly precise, minimally invasive, lung-conserving, robot-guided outpatient surgery where the patient can be released the same day.

#LungCancer #APLUS

Dr. Kim is a general thoracic surgeon with experience in all aspects of general thoracic surgery with national level expertise on minimally invasive thoracic surgery including the robotic lobectomy/segmentectomy, robotic esophagectomy, robotic thymectomy, robot assisted operations for benign esophageal diseases, and trachea and airway surgeries. He graduated from Johns Hopkins University with honors in Biophysics and as a member of Phi Beta Kappa in 1997 and then received his M.D. from Tufts University School of Medicine in 2002. He completed his residency in General Surgery at the University of Pennsylvania Hospital in 2009 and residency in Cardiothoracic Surgery at the Massachusetts General Hospital in 2012. Additionally, Dr. Kim completed a fellowship in Minimally Invasive Esophageal Surgery at the University of Pittsburg Medical Center and fellowship in Cardiothoracic Surgery at Mayo Clinic in 2010. Dr. Kim began his career on the faculty at University of Arizona in 2011 where he served as the Section Chief of Thoracic Surgery and was recruited to Northwestern in 2019 as the Director of Robotic Thoracic Surgery.

Watch/Read More
Categories
Lung Cancer

Oncotarget | Effects of Metformin and Rapamycin in Pancreatic Cancer [Video]

Oncotarget published this trending research paper on May 26, 2020, entitled, "An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma" by researchers from the Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; The Skip Viragh Center for Pancreas Cancer at Johns Hopkins, Baltimore, MD; Virginia Piper Cancer Center at HonorHealth, Scottsdale, AZ; Molecular Medicine Division, Translational Genomics Research Institute (TGen), Phoenix, AZ; Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Department of Nuclear Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai City, China; The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD.Abstract:Purpose: Metformin combined with the mTOR inhibitor rapamycin showed potential synergistic anti-tumor activity in preclinical studies in pancreatic ductal adenocarcinoma (PDA). This phase 1b study (NCT02048384) was conducted to evaluate the feasibility and activity of metformin +/– rapamycin in the maintenance setting for unselected patients with metastatic PDA (mPDA) treated with chemotherapy.Materials and Methods: Eligible patients with stable or responding mPDA after ≥ 6 months on chemotherapy were randomized 1:1 to metformin alone (Arm A) or with rapamycin (Arm B), stratified by prior treatment with FOLFIRINOX. Fluorodeoxyglucose (FDG) PET scans and peripheral blood mononuclear cells were obtained for exploratory analyses.Results: 22 subjects (11 per arm) received treatment per protocol. Median PFS/OS were 3.5 and 13.2 months respectively, with 2 year OS rate of 37%; there were no differences between arms. No responses were observed by RECIST; however, decreases in FDG avidity and/or CA19-9 were observed in several long-term survivors. Treatment related adverse events of Grade ≥ 3 occurred in 0% vs 27% of patients in Arm A vs B and were asymptomatic hematologic or electrolyte abnormalities that were not clinically significant. Improved survival was associated with low baseline neutrophil: lymphocyte ratio, baseline lack of assessable disease by PET, and greater expansion of dendritic cells following treatment.Conclusions: Metformin +/– rapamycin maintenance for mPDA was well-tolerated and several patients achieved stable disease associated with exceptionally long survival. Further prospective studies are needed to clarify the role of these agents in the maintenance setting and to enhance patient selection for such approaches.Press release - https://www.oncotarget.com/news/pr/an-exploratory-study-of-metformin-and-rapamycin-as-maintenance-therapy/Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27586DOI - https://doi.org/10.18632/oncotarget.27586Full text - https://www.oncotarget.com/article/27586/text/Correspondence to - Dung T. Le - dle@jhmi.edu Keywords - pancreatic cancer, mTOR inhibition, maintenance therapy, metformin, rapamycinAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia ContactMEDIA@IMPACTJOURNALS.COM18009220957

Categories
Lung Cancer

Live Study With Me For Finals | Pomodoro 50/10 | Quiet Study Session [Video]

✨⏰📚⬇️ CLICK BELOW FOR SCHEDULE ⬇️📚⏰✨ ✨ Live Study With Me Pomodoro✨ Seven Hours | 50/10✨ Hudson River Views in Manhattan✨ Current subscriber count → 2,010Hi friends :)Study with me as I work towards finals, while completing a PhD in Musicology at All Hallows College, DCU (Ireland). I'm currently living in Manhattan, NY and I always, ALWAYS work better when studying with other pals and peeps, so thank you for studying with me today. 🟢 Today's study with me is four sessions long.🟢 We start at 9:00am and we finish at 2:00pm.🟢 The timer/session is on the screen, and a bell will ring at the beginning and end of each session and break. 09.00 - 09.50 Session 109.50 - 10:00 Tea Break10.00 - 10.50 Session 210.50 - 11.00 Tea Break11.00 - 11.50 Session 311.50 - 12.00 Tea Break 12.00 - 12.50 Session 4 12.50 - 13.00 LUNCH, GREAT SUCCESS!I'm really enjoying the winter holiday vibes in Manhattan right now so I've got some candles lit, hot coffee at. hand and a crackling fire playlist on in the background.Let me know in the comments - what are you planning to study today? 🤓Hugs,Holly x_________________________________________________✨ FAQ ✨How old are you?I'm 29 and 13 months old.Where are you based?I'm Irish but have recently moved to MANHATTAN, BABY!!!!!What type of cancer are you getting treatment for?Stage IV oesophageal adenocarcinomaWhat drug are you on?An immunotherapy drug, called Nivolumab (Opdivo)What type of PhD research are you carrying out?Historical research into records of children's musical culture in IrelandWhich university are you studying at?All Hallows, College, Dublin City University____________________________✨ Say hi on Instagram :) or email @enquiries.hollyjane@gmail.com